FY2029 EPS Estimate for Trevi Therapeutics Lifted by Analyst

Key Points

• HC Wainwright has raised its FY2029 earnings estimate for Trevi Therapeutics to $1.79 per share from $1.66, while maintaining a "Buy" rating and a price target of $21.00.
• Trevi Therapeutics recently reported quarterly earnings of ($0.09) per share, exceeding expectations of ($0.10).
• Despite the positive outlook from some analysts, the stock has received mixed ratings, with one analyst downgrading it to "sell" while others maintain "buy" or "strong buy" ratings.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at HC Wainwright raised their FY2029 EPS estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Friday, August 8th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $1.79 per share for the year, up from their prior estimate of $1.66. HC Wainwright currently has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share.

A number of other equities research analysts have also recently commented on TRVI. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Monday, June 2nd. Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on shares of Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reduced their price objective on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $20.38.

Trevi Therapeutics Trading Down 0.8%

Shares of NASDAQ:TRVI traded down $0.06 during mid-day trading on Monday, reaching $7.43. The company had a trading volume of 268,552 shares, compared to its average volume of 1,821,884. The firm has a market cap of $904.46 million, a price-to-earnings ratio of -17.70 and a beta of 0.58. The company's 50-day moving average price is $6.66 and its 200-day moving average price is $6.01. Trevi Therapeutics has a one year low of $2.36 and a one year high of $8.11.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock valued at $25,000 after purchasing an additional 2,996 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after acquiring an additional 2,894 shares in the last quarter. Strs Ohio purchased a new position in Trevi Therapeutics in the first quarter worth $52,000. Farther Finance Advisors LLC grew its position in Trevi Therapeutics by 15,969.1% in the second quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company's stock worth $48,000 after acquiring an additional 8,783 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Trevi Therapeutics in the second quarter worth $56,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.